Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Cavalieri

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinomaEmily Ho, Loris De Cecco, Stefano Cavalieri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA studySalvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Thyroid : Official Journal of the American Thyroid Association|June 24, 2026
Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective StudySilvia Marchesi, Rebecca Romanò, Andrea Spagnoletti, et al.
JCO Precision Oncology|November 5, 2021
Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal CarcinomaStefano Cavalieri, Mara S Serafini, Andrea Carenzo, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Frontiers in Oncology|February 17, 2023
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocolStefano Cavalieri, Claudia Vener, Marissa LeBlanc, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumorsCaterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Plos One|May 23, 2020
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Cells|October 14, 2022
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck CancerStefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, et al.
Frontiers in Oncology|October 2, 2023
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructureLaura Botta, Tomohiro Matsuda, Hadrien Charvat, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinomaEmily Ho, Loris De Cecco, Stefano Cavalieri, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA studySalvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Thyroid : Official Journal of the American Thyroid Association|June 24, 2026
Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective StudySilvia Marchesi, Rebecca Romanò, Andrea Spagnoletti, et al.
JCO Precision Oncology|November 5, 2021
Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal CarcinomaStefano Cavalieri, Mara S Serafini, Andrea Carenzo, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Frontiers in Oncology|February 17, 2023
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocolStefano Cavalieri, Claudia Vener, Marissa LeBlanc, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumorsCaterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Plos One|May 23, 2020
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapySimon Keek, Sebastian Sanduleanu, Frederik Wesseling, et al.
Cells|October 14, 2022
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck CancerStefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, et al.
Frontiers in Oncology|October 2, 2023
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructureLaura Botta, Tomohiro Matsuda, Hadrien Charvat, et al.
Pageof 14